Drug intelligence / Profile preview

Eniagor

Development stage: Unknown
Lead developer: Apsen Farmacêutica
Modality: Small Molecules
Administration: Topical

Overview

Eniagor is a topical solution developed by Apsen Farmacêutica S.A. containing 5% minoxidil (50 mg/mL). It is specifically indicated for the treatment of androgenetic alopecia (hereditary baldness) in adult men. Minoxidil, the active ingredient, is a small molecule vasodilator that is thought to stimulate hair growth by opening ATP-sensitive potassium channels in the hair follicles, which prolongs the anagen (growth) phase and increases follicle size. Eniagor is formulated as a topical scalp solution and is contraindicated for use in women.

Brand names: Eniagor
Other names: minoxidil

Targets

KATP channel (ATP-sensitive potassium channel)ATP-sensitive potassium channel, SUR2/Kir6-containing channels

Beyond the preview

Go deeper on Eniagor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eniagor.

Explore the full profile